Healthcare Resource Guide: Germany

Last Updated: October 2019

Germany Statistics


Market Entry

Current Market Trends

Main Competitors

Current Demand

Registration Process



Trade Events

Statistics Snapshot

CS Contacts

Capital: Berlin

Population: 82.9 million

GDP: USD $3.68 trillion

Currency: Euro

Language: German


The German Medical Equipment Market 2017-2020




2019 (proj.)

2020 (proj.)

Market Size





Local Production















Imports from the U.S.





Total Market Size = (Total Local Production + Total Imports) – (Total Exports)

Data Sources: Spectaris Trade Association; BVMED Trade Association; Eucomed; Statista (German Federal Statistics Office)

General statistics on Germany is available at: This information is published by the German Federal Statistics Office.

Germany has a long history of producing high quality medical equipment, with an emphasis on diagnostic imaging, precision medical and dental instruments, and optical technologies. Not only is Germany the third-largest market in the world after the United States (U.S.) and Japan, but it is also by far the largest European market, twice the size of the French market and three times as large as those of Italy, the United Kingdom (UK) and Spain. The German medical devices market ranks no. 1 in Commerce’s Top Market Reports.

The Healthcare/Life Sciences (HCT) industry is a priority both for the European Union (EU) and Germany as reflected in the European Regional Development Fund (ERDF – or EFRE in German) program 2014-2020 and the German Länder implementation and tendering of this program. “Horizon Europe,” a European Incentive Program for Research and Innovation agreed upon by the EU Council and Parliament and scheduled to begin on Jan. 1, 2021, also focuses on health and health sector related R&D and innovation. Projects will focus on smart health and aging, rollout of digital models of care, and value-based care. This should result in increased opportunities for U.S. suppliers to participate in healthcare infrastructure and hospital development projects and to partner with German and EU firms. The German healthcare system lags in digitalization and digital solutions compared to other EU countries and the German government is taking steps to mandate progress, offering more opportunities for innovative U.S. health solutions providers.

Medical Technologies is the key sector of the HCT industry. Germany is Europe’s largest market for medical devices, accounting for roughly $41 billion annually. Key industry drivers include the power of innovation, a solid financial basis of the industry (in which 80 percent of businesses are small to medium sized enterprises (-SMEs), and a vibrant startup scene. Within the EU, Germany is the largest importer as well as exporter of medical devices. All major U.S. suppliers, such as GE Healthcare, Johnson & Johnson, Becton Dickinson, Abbvie, Stryker, Zimmer, 3M, McKesson, Cardinal Health, Henry Schein, and Medline, have subsidiaries in Germany. U.S. medical device exporters continue to hold a 28-30% share of the German import market.

Germany has a strong healthcare system in terms of infrastructure, hospital beds, and trained staff. In 2017, there were 497,182 beds in 1,942 hospitals (around 560 public hospitals, 662 non-profits, and 720 private hospitals), 1,142 rehabilitation centers, and 19,748 pharmacies. Well-established infrastructure makes the healthcare industry the largest employer in Germany with 7.3 million employees currently, amounting to 16.6% of the labor market total. One out of six jobs in Germany is linked to the healthcare sector, which generates $413 billion, or roughly 12% of Germany’s gross natural product; at $149 million, it also contributes 8.4% to Germany’s export total. The German medical device market grew by 4.2% in 2018 and is expected to continue with 4-6% growth rates through 2021, as the health economy is digitalized and the 2-digit investment backlog in the hospital market is confronted. Business Monitor even estimates the German medical device market will grow a 2018-2023 Compound Annual Growth Rate of 7.1%.

Return to Top

Market Entry

The German market for medical devices is regulated by German and EU directives, standards, and safety regulations. The EU Medical Device Regulation (MDR) will take effect on May 26, 2020, with increased testing, certification and compliance requirements. The complementary IVD Regulation will come into effect in May 2022. U.S. exporters are well-advised to inform themselves about MDR and obtain public or private sector counseling and assistance regarding the possible impact of their market entry plans into Germany. Companies seeking market entry should also carefully map their distribution strategy depending on their target group(s). CE marking is mandatory for selling medical devices in Europe. Entry strategies to be considered are top-down or bottom-up marketing, picking the right partners and ensuring patient- and customer-centric system solutions and support. Most medical equipment imported into Germany is either sold directly through a local subsidiary with a field sales force, through medical distributors with an established distribution network, often on a regional/territorial basis, or through appointed agents or manufacturer representatives. Local representation or market presence is essential when considering differing standards and certifications, warehousing costs, maintenance, accessibility, and local marketing/sales preferences/discussions. An agency agreement is often a cost-effective mechanism to enter the market, but under German law - even if the agent’s performance is not satisfactory - it can be difficult and costly to terminate an exclusive arrangement. A representation or distributorship agreement may be harder to arrange, but the German associate will, in fact, purchase the product to be sold, thus sharing the market risk. Licensing, partnering with large corporate partners, or buying a local firm provides an alternative in times where traditional distributors are often bought up by corporations and the market increasingly consolidates.

Return to Top

Current Market Trends

Demand for medical technologies and supplies will mainly be driven by demographics and a substantial increase in the number of patients. Germany’s population still accounts for 20% of the total population in Western Europe and is increasingly aging. Chronic disease prevalence, a sophisticated healthcare system with highly-qualified workers, high healthcare spending, universal healthcare coverage, and facilities turning to innovative technologies as revenue-generating optional procedures all herald well for U.S. healthcare exports.

By 2050, the 65 and over age group is forecast to expand to 23 million, up from an estimated 17 million in 2012. The German medical technology industry is a highly innovative and dynamic sector. One third of sales are generated by devices that are less than three years old and approximately 9% of all sales are reinvested in research. The German healthcare system is also among the best in the world regarding the uptake of new technologies. More than two thirds of German physicians are seeing innovation as the key element in maintaining the high standards of the German healthcare system. Hospitals can introduce innovative technologies. The German medical device sector, therefore, remains highly attractive for investors and continues to provide excellent potential for U.S. suppliers of innovative and price-competitive products, particularly in high tech imaging, minimally invasive surgery, big data management, telemedicine, and other key areas. The July 2017 Business Monitor report predicted a 5% annual growth rate for the next five years with a positive outlook for the European medical markets, including expansion of the private health segment, upgrade of hospitals and a strong import flow in addition to good local production capabilities. According to BMI, Europe is the most attractive region to commercialize a medical device, with Germany and the UK ranking as numbers 1 and 2. Germany is a perfect “test lab” for innovative medical devices and technologies as well as a playground for collaborative R&D.

Leading HCT sectors include: Health IT, pharmaceuticals, medical biotechnology and dental products.

  • Health IT: The period 2019-2021 will be decisive for Germany to catch up to its EU neighbors on digitalization and electronic patient records and medication management. This should present excellent opportunities for U.S. healthIT providers. HealthIT applications represent more than $320 million at present, with numerous projects throughout Germany and a University Hospital excellency network which drives innovation in key diseases such as stroke, Alzheimer’s, cancer, and diabetes. An aging society with significant rates of chronic disease, rollout of e-health patient portals by public health plan providers, and high Internet and mobile phone penetration, make Germany a strong healthIT market that offers good potential to specialty solution providers. From 2014 to 2017, revenue in German m-health increased by CAGR 22% (Source: GTAI) and the 2-digit growth is expected to continue. Germany has an excellent base for healthIT, with a startup-friendly environment and over 80 % of its workforce holding a degree. This makes it a very strong market for m-health and e-health products and services. The strong German medical technology clusters develop telehealth and telemedicine solutions and, in cooperation with hospitals and industry, form excellency clusters for oncology, neurological disorders, and chronic disease management. The German government’s medical informatics initiative aims to improve medical R&D and patient care through innovative IT solutions for specific applications and integrated health data centers. The multi-million-dollar funding scheme should pose excellent opportunities for U.S. solutions providers. E-procurement and e-commerce, Machine-to Machine communication (M2M), mHealth/apps and big data applications are areas of digitalization, in addition to telehealth and telemedicine, with windows of opportunities for U.S. suppliers.
  • Pharmaceuticals: The German pharmaceuticals market was valued at $60.5 billion in 2017 and remains one of the most attractive worldwide over the coming years. According to a report by GlobalData, the German pharmaceutical market is expected to grow to 67.3 billion EUR by 2021. Growth is driven by the aging population and chronic diseases. It is regarded as a test market for other EU countries for pricing and distribution. In 2017, the German pharmaceutical industry manufactured products worth EUR 30.6 billion, an increase of 4.7% over the previous year. Exports of pharmaceuticals increased by 6.8%, generating sales of $88.9 billion, while imports were up by 8% to $62.2 billion in the same period. On June 27, 2019, Germany became the 27th EU Member State in the EU-U.S. mutual recognition agreement for inspections. As a result, GMP inspections can be carried out by the respective national bodies, FDA and EMA, in equivalence.
  • Medical Biotechnology: Medical Biotechnology: Germany is Europe’s largest biotechnology market. In 2017, 646 dedicated biotechnology companies generated a turnover of $4.6 billion; initial estimates for 2018 put the turnover at $4.8 billion. R&D spending in the same timeframe registered $1.2 billion. Growth sectors in Germany’s biotech industry remain unchanged and continue to focus on new drug development and diagnostics, such as early disease detection. More than half of Germany’s red biotech companies are in the preclinical stage. Sales of biopharmaceuticals in Germany increased to $11.5 billion in 2017, a growth of 10.3% compared to 2016. Growth was seen in nearly all fields of application, particularly in drugs treating immunological (e.g. rheumatic) diseases and cancer. In-vitro diagnostics (IVD) are an important growth driver in the market, with more than two-thirds of all clinical diagnoses being made through IVDs. With more than $2.3 billion in annual revenue, Germany represents the largest IVD market in Europe and second worldwide behind the U.S. Germany’s biotech clusters (aka “BioRegions”) are Europe’s leading research and development hubs, and important partners for industry/academic R&D and technology transfer. Biotech is strong in Bavaria, North Rhine-Westphalia, Baden-Wuerttemberg, and the Berlin Brandenburg region. Some of the largest and most reputed clusters are in the Rhine-Neckar Triangle (Heidelberg), Cologne/Dusseldorf, Berlin/Brandenburg, and Munich. Biotech is a priority for the EU and German governments and is central to Germany’s economic and innovation policy. Biotech action plans focus on diagnostics, therapy and preventive medicine in (bio) medical research and care, and research-based medical technologies in specialized clusters. Germany’s participation at BioEurope, and in the world’s leading annual biotech event BIO in the U.S., is of great importance to both countries.
  • Dental: U.S. exports of dental equipment and supplies to Germany amounted to $112 million and dental laboratory equipment was $49 million in 2017. Germany has the biggest dental market in Europe, valued at $13.1 billion. Over 200 companies are actively exporting, with heavyweights Henry Schein, Danaher Corp. and Dentsply having major market share. Germany is Europe’s largest market for dental equipment. Total sales of dental products from 200 VDDI member companies, which employ more than 20,700 people, amounted to $6 billion (+5%) in 2017. The major U.S. dental technology supplier, Henry Schein, has a subsidiary in Germany and is one of the largest distributors in in the German dental market, with annual sales of more than $123 million and an estimated 10% market share. Many U.S. dental technology exporters consider the German market the “test lab” for Europe and make it the first stop for European rollout. Germany hosts the world’s largest biennial dental trade show, IDS, making Germany a premier marketplace for U.S. companies to reach their global partners and buyers. The U.S. dental industry, represented by 200+ U.S. exhibitors, converges every other year for the four-day IDS trade show that brings together industry professionals from all over the world. The 2018-2023 CAGR market growth is estimated at 5.8% by BMI research.

Return to Top

Main Competitors

The German market for medical devices is sophisticated and well served. Germany has a handful of large producers, headed by Siemens Healthineers, B. Braun and Fresenius. 95% of the German medical technology industry is characterized by Small to Medium Enterprises (SME) or sub-groups of larger companies. Almost 1,200 SME businesses (more than 20 employees) employ over 125,000 people and 11,300 smaller businesses employ around 75,000 people. 95% of all companies employ less than 250 employees and rarely does one company represent more than 2% of the entire sector. In addition, foreign industry giants such as Philips (NL), Hitachi (Japan) and Toshiba (Japan) are well entrenched. GE Medical, Medtronic, Agilent, 3M Healthcare, Hollister, Abbott, and Johnson & Johnson are only a few of the many German subsidiaries of U.S. medical device suppliers.

As a result of a conservative domestic market, the German medical technology industry relies heavily on export markets for continued growth. On average, German medical technology companies export 64% of their products. In 2017, German medical device export sales were up 2.5% to a total of EUR 26 million, with 50.9% going to other European countries and 19% to North America. Next to a strong German manufacturing base, imports supply around three-quarters of the German medical market. U.S. medical device exporters to Germany continue to hold a 27-30% import market share, depending on the product and exported goods. U.S. medical technology exports totaled EUR 3.9 billion to Germany in 2015 and the U.S. is the top exporter to Germany, ahead of Switzerland, China, and Japan. U.S. suppliers of innovative and price-competitive products especially can compete strongly on the German market.

Return to Top

Current Demand

The current German government has proposed several new health plans to improve and ensure the quality of hospitals and doctor offices and provide the best healthcare to patients of any age group. Since January 1, 2015, it is mandatory to have an electronic health card which stores personal patient data. The new Care Provision Strengthening Act (Versorgungsstärkungsgesetz) creates incentives for doctors to open their offices in rural areas due to an aging demographic among medical staff, and the associated closures of many doctor offices. In addition, the Hospital Structure Act (Krankenhausstrukturgesetz) lays out the quality standards that hospitals must meet. Large scale cost savings and more hospital efficiency are expected. The new Digital Care Law (DVG-Digitale Versorgungsgesetz) has been submitted for approval and will take effect by the end of 2019, strengthening digital patient care solutions.

The German government’s health informatics funding initiative and the German states’ initiatives on healthcare digitization offer good opportunities for U.S. firms to engage in Germany. An example would be a procurement for NRW Public Hospitals re-organizing their system and reconstructing and upgrading existing facilities. In a four-year span, U.S. companies will have the opportunity to participate in consortia or as sub-contractors.

The German Government is jump starting a “Medical Informatics” funding scheme as part of the Health Research Framework Program. In an aging society where diseases like cancer, dementia, and various cardiovascular, metabolic, and muscular ailments will become more prevalent, it is important to improve the exchange of data across different institutions and locations. The aim of the scheme is that faster diagnoses and treatments will help cut costs and help individuals receive faster and more precise care.

For more information on procurements you can get involved in, please visit

Germany’ healthcare market offers more than just agents and distributors; it is full of different opportunities along the supply chain, including design and research and development collaboration, strategic partnerships, equity partner and investor engagements, mergers and acquisitions, project collaboration, and other types of opportunities for SMEs to get involved with to grow business and expand in the market.

Interest in and demand for innovative technologies is high in Germany. German healthcare players regularly travel to the U.S.; many doctors have studied in the U.S. or have participated in exchange programs, and there is a natural affinity and many ongoing partnership and collaboration projects. Demand is high for ehealth including infrastructure, health apps, and security management, minimally invasive, home care/technical aids, orthopedic and implant, and diabetes management technologies as well as oncology diagnostics, molecular diagnostics, personalized medicine, and patient management technology/systems.

Return to Top

Registration Process

CE Marking, Medical Devices Directive and New MDR

On May 26, 2017, the new MDR and IVD Directives took effect. Changes include expansion of the scope of products covered, more rigorous requirements for clinical evaluation, mandatory UDI mechanisms, and increased post-market surveillance by EU Notified Bodies. Manufacturers with approved devices on the market will have three years to demonstrate compliance with the new MDR. Exemptions are under negotiation currently. The competent authority for implementing the new EU medical devices directive is the Federal Health Ministry through BfArM, the executive registration authority, and Paul-Ehrlich-Institute.

The CE mark signifies that a product fulfills all necessary EU requirements. CE marking is now a legal requirement for a wide range of equipment manufacturers in Germany. Certification requirements for use of the CE mark vary depending on the product. For some, such as those in the MPG low risk class I, the manufacturer (or importer/ authorized representative, if the product is manufactured outside the EU) may self-certify compliance with EU requirements and affix the mark; for others, the certification of a Notified Body (an accredited certification agency such as the TUEV) will be required. For the medical aids sector, the workability and safety of a product is now considered satisfied by CE marking. The CE mark is a visible indication that the manufacturer signed a “Declaration of Conformity” prior to affixing the CE mark, claiming compliance with all relevant CE marking directives in force.

All electro-medical equipment in Germany must be suitable for use with 220 Volt, 50 cycle electrical current, and should have VDE or TUEV approval. A UL approval is not a substitute but is helpful to obtain “GS/VDE”, or “GS/TUEV” approval in Germany. “GS” stands for “gepruefte Sicherheit” (safety tested). Although “GS” and the “VDE” (or “GS and TUV”) marks are not required by law, they are highly recommended for marketing electro-medical goods in Germany. These labels denote high product safety; German consumers look for these labels as Americans do for the “UL” mark.

The U.S. Product Safety Testing Institute, Underwriters Laboratories (UL), the VDE Testing and Certification Institute, and the TUEV Product Service have formed a strategic alliance for testing of electromagnetic compatibility (EMC) which has resulted in a globally recognized EMC test mark. For manufacturers of electrical and electronic products, this cooperation has led to a substantive simplification of EMC testing. Through a single test carried out by one of these three partners, a product can now be awarded an international EMC mark, which replaces the national test marks in the major world markets of Europe, the USA and Japan.

To place a medical device on the market, a manufacturer, authorized representative, reseller, or distributor must observe all relevant legislation. A list of Notified Bodies can be downloaded from the EU Commission website. Currently, only four Notified Bodies, BSI, TUEV Sued Product Service, IMQ and Dekra, have been certified for testing for MDR.

Return to Top


The reimbursement of innovative medical devices depends upon whether the device will be used in a hospital (inpatient) or ambulatory (outpatient) setting. In the inpatient setting, new medical services are reimbursed without prior assessment, if fundamental principles of quality and cost-effectiveness are not violated. In the inpatient sector, billing of services is based on DRGs, a fee-per-case system. There are roughly 1,200 different DRGs in Germany. The DRG classification system uses case-related coding rules which apply to diagnoses (ICD-10 German modification) and procedures (Operations and Procedure Codes-OPS). With the DRG case-based flat rate, all costs related to the inpatient diagnosis/treatment are covered including medical devices. The DRG system is revised annually by InEK-Institute for the Remuneration System in Hospitals. The amount of each DRG compensation is based on data collected continuously from several hundred German clinics.

The new medical device is reimbursed immediately if it is part of an established method which has been implemented already in the reimbursement system. For innovative devices and technologies not yet in the system, pathways such as the NUB (novel diagnosis and treatment methods) procedure should be explored, particularly when the device is significantly more expensive than current methods. For a more detailed description of NUB methods and timelines, please contact a country specialist listed below.

Outpatient services are mostly provided by private practitioners (around 148,000), which, by law, are members of their regional Statutory Health Insurance (SDI) accredited physicians association (ASHIP). The physicians are paid by their respective ASHIP which in turn is paid by the public insurance funds. ASHIP funds pay their members based on a uniform evaluation scale known as EBM. Physicians are only able to invoice services that appear on the EBM. The EBM is set by a committee of SHI representatives and ASHIP representatives, together called the Evaluation Committee (in German: Bewertungsausschuss). The payment scheme for outpatient physicians is based upon a mix of services delivered, number of patients served, and a fixed budget distribution system. Any novel diagnostic/therapeutic device/procedure must be evaluated before being reimbursed. Only procedures which “show a benefit, are medically necessary and efficient” can be reimbursed. The decision on reimbursement must be ratified by the Federal Joint Committee, which may request a Health Technology Assessment (HTA) by the Institute for Quality and Efficiency in Healthcare (IQWIG). The actual payment amount of an EBM-listed procedure is the responsibility of the Evaluation Committee. In case of an approval, the medical service/device must be covered by SHI and will then be reimbursed throughout Germany by all SDI insurance funds. U.S. companies interested in filing for reimbursement are almost certain to need a local partner for the process. A country specialist can provide a list of resources upon request.

Return to Top


Firms exporting medical devices to Germany will not encounter any direct trade barriers or quotas. Non-tariff, indirect trade barriers could include the complex German reimbursement system, the need for additional registration procedures in the case of medical assistive technologies, for example, or products sold in pharmacies, with the requirement to apply for HMV or PZN codes, respectively. For Class 2 medical products, the German medical products law requires manufacturing and distribution control and quality control documentation. The new EU Medical Devices Directive (in addition to Brexit) will result in a shortage of Notified Bodies, contains tight transition periods, and will result in substantively higher expenditures and cost for clinical evaluations of medical products, according to the German Advanced Technology Association, BVMED. In addition, the new medtech evaluation procedure (according to §137h SGB V (German Social Law), in effect since the fall of 2016) considerably changes the established annual applications of hospitals for first-time, high-risk, especially invasive NUBs (novel investigative and treatment methods) with DRG Institute InEK. BVMED has published guidance on new NUB procedures, in German. BVMED’s Olaf Winkler (email: is the contact for further questions.

Return to Top

Procurement & Tenders

The legal basis for a tender can either be the national ‘domestic public procurement law’ or the standardized EU public procurement law as per §97ff. GWG. The national public procurement law serves only to ensure as economical a purchase of services as possible by the (public) payer; the EU public procurement law aims to ensure standardized access for companies in all EU member states to procurement markets within the EU. The legal basis is outlined in the EU procurement law. However, the requirements of the EU procurement law, compared to the national procurement law, are more formal. Nevertheless, the EU procurement law – different from the national procurement law – offers the bidders effective legal protection and therefore an instrument that allows for an official legal review of the correctness of the procurement process and decision and, if necessary, the possibility to have another check carried out by the courts. The purely national procurement law does not offer this option. An essential criterion of demarcation is the exceedance of a standard value. In the area of delivery and services, which must be put out to tender according to standard official contracting terms, this amount is EUR 206,000. Only when the net total order value over the entire duration exceeds this value does the EU procurement law apply. A public employer issuing a public tender with a net order value above the threshold where no obvious exceptions apply is a condition for intervention by the EU public procurement law regime, however. The obligation to tender according to the EU public procurement law is therefore aimed at public hospital operators such as communal hospitals, university hospitals, other public hospitals (such as those partly funded by trade associations), and the respective pooling agreements, for instance in the form of purchasing associations. The European tender database is:

Hospital Tenders in Germany, if below the EUR 200,000 threshold, are published in:

A good summary of health insurance options in Germany can be found here: A more detailed overview, with historical track, is available as a booklet here:

Return to Top

Trade Events

XPOMET Medicinale - October 10-12, 2019

XPOMET© Medicinale is an international festival platform to showcase best practice and highlight trends in global healthcare and forecast future developments in health and tech.

Creative disruption and knowledge transfer are the backbone of Medicinale. Over 5,000 international guests will hear from over 150 inspiring speakers, engage in public and private deep dives and join more than 200 of the most inventive companies with the aim of enabling and fostering new transdisciplinary solutions, business models and partnerships in medicine and life sciences. The Impact Farm will be hosting its top-tech Hackathon #healthhackathon19 and an outstanding portfolio of international start-ups will be competing to show off their most recent innovations. For more information contact:

A+A 2019 (Safety + Health at the Workplace) - November 05-08, 2019

With over 63,000 visitors and over 1,600 exhibitors A+A is the world's largest and most important specialist trade fair for all aspects of safety and security. Core products/technologies of A+A are safety, security, and corporate health management including prevention and therapy of work-related illnesses. For more information contact:

BIO-EUROPE 2019 - November 10-13, 2019 - Hamburg, Germany

The 22nd Bio-Europe event will be the largest biotechnology partnering conference held in Europe. More than 3,000 global decision makers from biotechnology, pharma and finance annually attend BIO-Europe to identify new business opportunities and develop strategic partnerships. BIO-Europe features the industry’s most advanced web-based partnering system enabling delegates from all parts of the biotechnology value chain to quickly identify, engage, and enter strategic relationships that drive their business successfully forward. Special offers to international visitors include International Delegations Reception and In-Depth Introduction to the German Biotech Market. For more information contact:

MEDICA with Compamed - November 18-21, 2019 /

Considered the world's most important and largest international fair for medical equipment, the annual MEDICA draws 129,000 trade visitors from more than 70 countries. Over 4,800 exhibitors from 67 foreign countries exhibit at the show. Parallel to Medica, Compamed will take place as the marketplace for suppliers to the medical manufacturing industry, with 728 exhibitors from 37 countries. The show offers two USA Pavilions in the Diagnostics and Medical Product Halls plus the USDOC-organized USA CEO Center as meeting space on the show floor. Special offer for U.S. companies includes a Personal Assistant for Appointment-Setting; Pre-show Promotion; International Delegations/USA Reception; and In-Depth Introduction to the International Medical Markets through Showtime program. For more information contact: or

FIBO 2020 - April 02-05, 2020

FIBO is the world’s leading trade show for fitness, wellness, and health. More than 700 exhibitors from 40 countries and more than 138,000 visitors attend FIBO every year. Approximately 25-30 U.S. companies participate in thematic halls for sports nutrition, nutritional supplements, sports equipment, health and wellness equipment, and service providers. FIBO offers a USA Pavilion organized by Kallman Associates and supported by the U.S. Commercial Service. For more information contact:

DMEA (formerly ConhIT) – Connecting Digital Health - April 21-23, 2020

DMEA is Europe's largest event for the health IT industry, with 11,000 participants and about 570 exhibitors from 27 countries in 2019. DMEA maps the entire healhIT supply chain. DMEA further develops into a platform for digital solutions that affect all players in the healthcare system today. The proven mixture of trade fair, congress, advanced training and numerous networking events makes this a no-miss event. For more information contact:

OTWorld (formerly, Orthopädie + Reha-Technik) - May 12-15, 2020 (biennial)

The orthopedic and rehabilitation industry's leading event worldwide with 548 exhibitors and over 20,400 international visitors. The event takes place every two years and combines the presentation of innovative technology and new products with professional training of the highest quality. In 2013 the event was re-named OTWorld, since the show is truly international in scope. The traditional USA Pavilion is organized by Kallman Associates and supported by the US Commercial Service. For more information contact:

38th IDS-International Dental Show - March 2021 (biennial)

IDS is the world’s leading trade show and sector meeting place for decision-makers from dental practices, dental labs, the specialist dental trade, and the dental industry. Over 2,200 exhibitors from 56 countries display their products and technologies to over 138,000 visitors from 151 countries. IDS offer a large Dental Trade Alliance organized USA Pavilion, which is supported by the U.S. Commercial Service. For more information contact:

Return to Top

Statistics Snapshot

Market Size

Healthcare spending (including investment)


... as percent of GDP


... of which spent on inpatient services (including long-term care)


... of which spent on pharmaceuticals/consumables


... of which spent on investments


… of which spent on outpatient services


… of which spent on administration


... of which spent on other


Hospitals, Procedures, Healthcare Professionals

Number of hospitals








Number of hospital beds


... available beds per capita



...of which in public hospitals


…of which in charitable hospitals


...of which in private hospitals


Number of surgical procedures

16.9 million

...of which on intestinal tract

2.5 million

...of which muscular-skeletal

4.7 million



...of which surgeons


...of which internists


...of which pediatricians







82.9 million

Life expectancy men/women

Men: 78.7 years; Women: 83.4 years

Infant mortality


Percent of population older than 65

21.4% (17.7 million)

...projection, 2030

26% (21.8 million)

Annual deaths


...caused by cardiovascular diseases


...caused by cancer


Prevalence of Diabetes as fastest growing chronic disease; 12.2% of population in 2017


Return to Top

U.S. Commercial Service Contact Information

Name: Anette Salama (Medical Devices)

Position: Senior Commercial Specialist, Lead Healthcare/Life Sciences


Phone: +49 211 737 767 60

Name: Sabine Winkels (Biotech; Pharma)

Position: Commercial Specialist, Healthcare/Life Sciences


Phone: +49 211 737 767 40

Name: Uta Kirst (Dental; HealthIT)

Position: Commercial Specialist, Healthcare/Life Sciences


Phone: +49 211 737 767 80

  Notice to Visitors!

  The link you have chosen will take you to a non-U.S. Government website.

  If the page does not appear in 5 seconds, please click this: outside web site is managed by the International Trade Administration and external links are covered by its website  disclaimer statement.

  Notice to Visitors!

  The link you have chosen will take you to a non-U.S. Government website.

  If the page does not appear in 5 seconds, please click this: outside web site is managed by the International Trade Administration and external links are covered by its website disclaimer statement.